11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 31.05.2026 Expectation: 4500 pips
Selling EURUSD from resistance
Yesterday at 11:21 AM 24
Period: 27.03.2026 Expectation: 900 pips
USDCAD resistance looms as overheating sets in
Yesterday at 11:04 AM 24
Period: 27.03.2026 Expectation: 1050 pips
AUDCAD thrives on monetary divergence
Yesterday at 10:06 AM 14
Period: 31.03.2026 Expectation: 800 pips
Buying Brent crude with $115 in view
Yesterday at 09:35 AM 29
Gold sell
Period: 31.03.2026 Expectation: 600 pips
Selling gold upon breaking $4,560
Yesterday at 08:46 AM 25
Period: 30.04.2026 Expectation: 2000 pips
SPX selloff to follow once it consolidates below $6,600
Yesterday at 08:46 AM 14
Go to forecasts